ClinicalTrials.gg
Active, not recruitingNCT07536048Updated Jun 11, 2026

A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years

An observational study in Epstein-Barr Virus (EBV) and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 2 sites in Australia. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 29 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Epstein-Barr Virus Infections with a site in Australia — 3 open to participants now, 5 under way, 2 of them phase 3. Epstein-Barr Virus Infections · Australia.

Started
2026
with 2 others
Observational
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Sanofi Pasteur, a Sanofi Company

Among the 10 studies in Epstein-Barr Virus Infections with a site in Australia, this one is one of 3 that started in 2026, is the only observational one, and was the 9th registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

3 of the 10 studies in Epstein-Barr Virus Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 29 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epstein-Barr Virus Infections with a site in Australia, or all of them as a file.
02

Study summary

This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.

This study will follow a cohort of approximately 100 EBV seropositive adults 18 to 29 years of age in Australia over a 6 or 12-month period.

Participants will not receive any study intervention (eg, study treatments, vaccines).

03

Conditions studied

  • Epstein-Barr Virus (EBV)
  • Healthy Volunteers
04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Approximately 100 EBV seropositive participants aged 18 to 29 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 29 years on the day of inclusion
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • Participants who are EBV seropositive based on serology testing

Exclusion criteria

Exclusion Criteria:

Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy participants who are EBV seropositive

    Procedure: Investigational Procedure

Interventions

  • ProcedureInvestigational Procedure

    It consists of prospective blood and saliva collections. Study without any IMP administration.

06

What researchers measure

Primary outcomes

  1. Number of participants with EBV DNA in blood and saliva at each study visit

    Time frame: 6 or 12 months

  2. Serology testing indicative of EBV reactivation, measured by anti-VCA IgG/IgM, anti-EBNA-1 IgG and anti-EA IgG at each study visit

    Time frame: 6 or 12 months

Secondary outcomes

  1. Levels of IgG antibodies binding to EBV antigens, measured at selected time points in a subset of participants

    Time frame: 6 or 12 months

  2. Levels of EBV nAbs in serum measured at selected timepoints in a subset of participants

    Time frame: 6 or 12 months

  3. Immunogenicity assessments at baseline to identify antibody signatures that may correlate with the occurrence of EBV reactivations during study period. Neutralizing and IgG binding assays will be performed in a subset of participants

    Time frame: 6 or 12 months

07

Study locations

2 sites
  • Griffith - University Clinical Trial Unit - Site Number : 0360001
    Gold Coast, 4222, Australia
  • University of Sunshine Coast - Site Number : 0360002
    South Brisbane, 4101, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 17, 2026
StartActual
Apr 20, 2026
Primary completionEst.
May 14, 2027
CompletionEst.
May 14, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07536048
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Apr 20, 2026
Primary completion
May 14, 2027 (estimated)
Completion
May 14, 2027 (estimated)
Last update
Jun 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion